CervoMed Inc. (CRVO) stock
CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.50−0.17 (-10.18%)
Close on Nov 17, 2026Market cap $22.68MP/E –Yield –
CervoMed r&d expenses
Research and development expenses are spending on new products and technology.
CervoMed's R&D Expenses for the twelve months ending Jun 30, 2026 was $21.33M, down 3.7% year over year. For fiscal 2025 it was $21.82M, up 16.1% from the year before. Over ten years it grew 18.9% a year on average. The highest annual figure on record is $21.82M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.82M | +16.1% |
| FY2024 | Dec 31, 2024 | $18.80M | +122.8% |
| FY2023 | Dec 31, 2023 | $8.44M | +531.4% |
| FY2022 | Dec 31, 2022 | $1.34M | -84.3% |
| FY2021 | Dec 31, 2021 | $8.50M | -9.8% |
| FY2020 | Dec 31, 2020 | $9.43M | +42.4% |
| FY2019 | Dec 31, 2019 | $6.62M | +15.1% |
| FY2018 | Dec 31, 2018 | $5.75M | +13.0% |
| FY2017 | Dec 31, 2017 | $5.09M | -29.8% |
| FY2016 | Dec 31, 2016 | $7.25M | +87.1% |
| FY2015 | Dec 31, 2015 | $3.88M | +35.5% |
| FY2014 | Dec 31, 2014 | $2.86M | +734.2% |
| FY2013 | Dec 31, 2013 | $342.92K | – |
| FY2011 | Dec 31, 2011 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.32M | -15.4% |
| Q1 FY2026 | Mar 31, 2026 | $5.14M | +6.2% |
| Q4 FY2025 | Dec 31, 2025 | $5.83M | -17.7% |
| Q3 FY2025 | Sep 30, 2025 | $6.04M | +17.9% |
| Q2 FY2025 | Jun 30, 2025 | $5.11M | +35.4% |
| Q1 FY2025 | Mar 31, 2025 | $4.84M | +71.9% |
| Q4 FY2024 | Dec 31, 2024 | $7.09M | +148.2% |
| Q3 FY2024 | Sep 30, 2024 | $5.13M | +186.1% |
| Q2 FY2024 | Jun 30, 2024 | $3.77M | +92.6% |
| Q1 FY2024 | Mar 31, 2024 | $2.81M | +53.5% |
| Q4 FY2023 | Dec 31, 2023 | $2.86M | +650.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.79M | +442.0% |
| Q2 FY2023 | Jun 30, 2023 | $1.96M | -7.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.83M | -24.4% |
| Q4 FY2022 | Dec 31, 2022 | $380.69K | -74.7% |
| Q3 FY2022 | Sep 30, 2022 | $330.54K | -84.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.11M | +6.9% |
| Q1 FY2022 | Mar 31, 2022 | $2.43M | -16.8% |
| Q4 FY2021 | Dec 31, 2021 | $1.50M | -41.7% |
| Q3 FY2021 | Sep 30, 2021 | $2.11M | -32.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.97M | -9.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.92M | +90.1% |
| Q4 FY2020 | Dec 31, 2020 | $2.58M | +55.8% |
| Q3 FY2020 | Sep 30, 2020 | $3.14M | +80.0% |
| Q2 FY2020 | Jun 30, 2020 | $2.17M | +43.1% |
| Q1 FY2020 | Mar 31, 2020 | $1.53M | -9.7% |
| Q4 FY2019 | Dec 31, 2019 | $1.66M | +21.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.74M | +49.0% |
| Q2 FY2019 | Jun 30, 2019 | $1.52M | +9.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.70M | -6.9% |
| Q4 FY2018 | Dec 31, 2018 | $1.37M | +19.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.17M | -33.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.39M | +17.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.83M | +81.2% |
| Q4 FY2017 | Dec 31, 2017 | $1.14M | -24.5% |
| Q3 FY2017 | Sep 30, 2017 | $1.76M | -9.4% |
| Q2 FY2017 | Jun 30, 2017 | $1.18M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.01M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.51M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.94M | – |
See a number that looks wrong?